The US FDA may have its hands full deciding how to limit the use of US WorldMeds LLC's 5-HT4 receptor agonist Zelnorm (tegaserod maleate), a drug designed for the treatment for irritable bowel syndrome with constipation (IBS-C), after an advisory committee delivered a split vote over the most appropriate target population.
On Oct. 17, seven of 12 members of the Gastrointestinal Drugs Advisory Committee voted that they expect the benefits of...





